Galderma recently announced the Phase 2 clinical trial results for its new ready-to-use investigational botulinum toxin, QM1114. The study successfully demonstrated the safety and efficacy of Galderma's liquid formulation of botulinum toxin type A for the treatment of frown lines. Derived from Galderma's proprietary strain of Clostridium botulinum bacteria and manufactured using an animal-origin free process, QM1114 has been designed and developed specifically for use in aesthetics. The Phase 3 clinical trial program will begin soon. "As a physician, I need to be confident that innovation in aesthetic treatment is the result of scientific rigor," says Joel Cohen, M.D., director of AboutSkin Dermatology and DermSurgery in Colorado, and investigator in the Phase 2 clinical trial. "I am encouraged by the results of the Phase 2 QM1114 study, which demonstrated initial safety and efficacy at all doses with high patient satisfaction. It is exciting to see the development of a new toxin formulation that can offer convenience and the potential to eliminate the need for reconstitution in my practice."